The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Sullivan-Klose, Theresa H.; Ghanayem, Burhan I.; Bell, Douglas A.; Zhang, Zhi Yi; Kaminsky, Laurence S.; Shenfield, Gillian M.; Miners, John O.; Birkett, Donald; Goldstein, Joyce A.

doi:10.1097/00008571-199608000-00007

Cited by 551 publications

(401 citation statements)

References 0 publications

Supporting

Mentioning

372

Contrasting

Unclassified

Order By: Relevance

“…Both transheterozygous CYP2D6*5/*10 and homozygous CYP2D6*10/*10 represent the IM phenotype. Because of this, in the Taiwanese population it is likely that the IM et al 1996) 0.021 (Nasu et al 1997) 0.011 (Yoon et al 2001) 0.06-0.09 (Scordo et al 2001;Sullivan-Klose et al 1996) 0.005 (Sullivan-Klose et al 1996 CYP2C19*2 0.324 (179) 0.32 (Goldstein et al 1997) 0.23 (Goldstein et al 1997) 0.209 (Herrlin et al 1998) 0.129-0.144 (Goldstein et al 1997;Shimizu et al 2003) 0.25 (Goldstein et al 1997) CYP2C19*3 0.05 (179) 0.055 (Goldstein et al 1997) 0.104 (Goldstein et al 1997) 0.116 (Herrlin et al 1998) 0 (Goldstein et al 1997;Shimizu et al 2003) 0 (Goldstein et al 1997) CYP2D6*5 0.055 (173) 0.072 (Ji et al 2002) 0.003-0.062 (Kubota et al 2000;Fukuda et al 2005) 0.017 …”

Section: High Prevalence Pm/um Genotype Frequencies In the Taiwanese mentioning

confidence: 99%

The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population

Liou

Lin

et al. 2006

J Hum Genet

View full text Add to dashboard Cite

Genetic polymorphisms of drug metabolizing enzymes, such as cytochromes P450 (CYPs), play major roles in the variations of drug responsiveness in human. The aim of this study is to identify the high prevalence (minor allele frequencies >1%) of the abnormal metabolite alleles of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Taiwanese population. The genotyping of the functional single nucleotide polymorphisms (SNPs) of CYPs were conducted by direct exon sequencing in 180 Taiwanese volunteers. Twenty-one unique SNPs including three newly identified SNPs were detected in the Taiwanese population. Six of the 21 SNPs in five genes showed frequencies more than 1%. The results indicated that it could be very useful and important in developing an inexpensive, convenient, and precise genotyping method for the high prevalence of CYPs metabolizing abnormal alleles in the Taiwanese population.

show abstract

Section: High Prevalence Pm/um Genotype Frequencies In the Taiwanese mentioning

confidence: 99%

The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population

Liou

Lin

et al. 2006

J Hum Genet

View full text Add to dashboard Cite

show abstract

“…We critically reappraised their findings using their primers originally reported by Stubbins et al 43 and the other primers by Sullivan-Klose et al 44 that were validated by us and others. [12][13][14]16 We found that the nucleotide sequences of the PCR products amplified by the primers of Leung et al 32 and Stubbins et al 43 differed from those amplified by the latter primers 44 and the authentic DNA sequence of CYP2C9 exon 4. Using the latter PCR primers we found no SNPs in exon 4 of CYP2C9 in Japanese patients (unpublished data).…”

Section: Effects Of Cyp2c9 Genotypes On (S)-warfarin Metabolismmentioning

confidence: 76%

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

Takahashi

Echizen

2003

Pharmacogenomics J

View full text Add to dashboard Cite

“…51 However, CYP2C9*3 confers roughly 10 to 30% of the enzymatic activity of the wild type, depending on the substrate being studied. [51][52][53][54] Genomic factors play a role in the extent to which ibuprofen is eliminated from the body. A study published in 2004 comparing the role of CYP2C8 and CYP2C9 polymorphisms in pharmacokinetic profile of ibuprofen noted a significant difference in the clearance of ibuprofen when comparing CYP2C8*1/*1 (4.04 l h À 1 ) with CYP2C8*3/*3 (0.40 l h À 1 ).…”

Section: Propionic Acid Derivativesmentioning

confidence: 99%

Pharmacogenetics of nonsteroidal anti-inflammatory drugs

2012

View full text Add to dashboard Cite

With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacotherapy as a whole. Utilizing these ever-expanding branches of science to nonsteroidal anti-inflammatory drugs (NSAIDs) can provide novel opportunities to affect patient care. With a wide range of NSAID choices available as treatment options for relieving pain and/or reducing inflammation or fever, a more systematic way of selecting the ideal agent for the patients based upon their genetic information could spare them from a potentially permanent health-care condition. Furthermore, if a patient possesses or lacks certain alleles, serious adverse events can be anticipated and avoided. The tailoring of drug therapy can be achieved using the published data and cutting-edge genetic testing to attain a higher standard of care for patients.

show abstract

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Cited by 551 publications

References 0 publications

The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population

The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

Pharmacogenetics of nonsteroidal anti-inflammatory drugs

Contact Info

Product

Resources

About